Critical Survey: STRATA Skin Sciences (NASDAQ:SSKN) & Medigus (NASDAQ:MDGS)

Medigus (NASDAQ:MDGSGet Rating) and STRATA Skin Sciences (NASDAQ:SSKNGet Rating) are both small-cap business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Medigus and STRATA Skin Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medigus 0 0 0 0 N/A
STRATA Skin Sciences 0 0 0 0 N/A

STRATA Skin Sciences has a consensus target price of $2.00, suggesting a potential upside of 135.29%. Given STRATA Skin Sciences’ higher possible upside, analysts plainly believe STRATA Skin Sciences is more favorable than Medigus.

Valuation & Earnings

This table compares Medigus and STRATA Skin Sciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medigus $10.12 million 0.51 $6.79 million N/A N/A
STRATA Skin Sciences $29.98 million 0.98 -$2.71 million ($0.17) -5.00

Medigus has higher earnings, but lower revenue than STRATA Skin Sciences.

Insider & Institutional Ownership

9.2% of Medigus shares are owned by institutional investors. Comparatively, 32.2% of STRATA Skin Sciences shares are owned by institutional investors. 2.2% of Medigus shares are owned by company insiders. Comparatively, 40.4% of STRATA Skin Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Medigus and STRATA Skin Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medigus N/A N/A N/A
STRATA Skin Sciences -17.86% -26.52% -11.87%

Summary

STRATA Skin Sciences beats Medigus on 5 of the 9 factors compared between the two stocks.

About Medigus

(Get Rating)

Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

About STRATA Skin Sciences

(Get Rating)

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

Receive News & Ratings for Medigus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigus and related companies with MarketBeat.com's FREE daily email newsletter.